TG Therapeutics Inc.(TGTX)今日盘中股价大幅上涨5.12%,引起了市场的广泛关注。
消息面上,公司披露了2025年第四季度及全年度财务业绩报告,并同时宣布上调其核心产品Briumvi的全年收入指引,这反映出该药物在市场推广和患者接纳度方面的积极进展,增强了投资者对公司未来增长潜力的信心。
此次财报的公布和收入预期的上调,为投资者提供了更明确的价值锚点,可能直接推动了股价在交易时段的强劲表现。
TG Therapeutics Inc.(TGTX)今日盘中股价大幅上涨5.12%,引起了市场的广泛关注。
消息面上,公司披露了2025年第四季度及全年度财务业绩报告,并同时宣布上调其核心产品Briumvi的全年收入指引,这反映出该药物在市场推广和患者接纳度方面的积极进展,增强了投资者对公司未来增长潜力的信心。
此次财报的公布和收入预期的上调,为投资者提供了更明确的价值锚点,可能直接推动了股价在交易时段的强劲表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.